Cargando…
Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
The last few years important changes have occurred in the field of diabetes treatment. The priority in the therapy of patients with diabetes is not glycemic control per se rather an overall management of risk factors, while individualization of glycemic target is suggested. Furthermore, regulatory a...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855136/ https://www.ncbi.nlm.nih.gov/pubmed/35211246 http://dx.doi.org/10.4239/wjd.v13.i2.85 |
_version_ | 1784653588769800192 |
---|---|
author | Florentin, Matilda Kostapanos, Michael S Papazafiropoulou, Athanasia K |
author_facet | Florentin, Matilda Kostapanos, Michael S Papazafiropoulou, Athanasia K |
author_sort | Florentin, Matilda |
collection | PubMed |
description | The last few years important changes have occurred in the field of diabetes treatment. The priority in the therapy of patients with diabetes is not glycemic control per se rather an overall management of risk factors, while individualization of glycemic target is suggested. Furthermore, regulatory authorities now require evidence of cardiovascular (CV) safety in order to approve new antidiabetic agents. The most novel drug classes, i.e., sodium-glucose transporter 2 inhibitors (SGLT2-i) and some glucagon-like peptide-1 receptor agonists (GLP-1 RA), have been demonstrated to reduce major adverse CV events and, thus, have a prominent position in the therapeutic algorithm of hyperglycemia. In this context, the role of previously used hypoglycemic agents, including dipeptidyl peptidase 4 (DPP-4) inhibitors, has been modified. DPP-4 inhibitors have a favorable safety profile, do not cause hypoglycemia or weight gain and do not require dose uptitration. Furthermore, they can be administered in patients with chronic kidney disease after dose modification and elderly patients with diabetes. Still, though, they have been undermined to a third line therapeutic choice as they have not been shown to reduce CV events as is the case with SGLT2-i and GLP-1 RA. Overall, DPP-4 inhibitors appear to have a place in the management of patients with diabetes as a safe class of oral glucose lowering agents with great experience in their use. |
format | Online Article Text |
id | pubmed-8855136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-88551362022-02-23 Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment Florentin, Matilda Kostapanos, Michael S Papazafiropoulou, Athanasia K World J Diabetes Minireviews The last few years important changes have occurred in the field of diabetes treatment. The priority in the therapy of patients with diabetes is not glycemic control per se rather an overall management of risk factors, while individualization of glycemic target is suggested. Furthermore, regulatory authorities now require evidence of cardiovascular (CV) safety in order to approve new antidiabetic agents. The most novel drug classes, i.e., sodium-glucose transporter 2 inhibitors (SGLT2-i) and some glucagon-like peptide-1 receptor agonists (GLP-1 RA), have been demonstrated to reduce major adverse CV events and, thus, have a prominent position in the therapeutic algorithm of hyperglycemia. In this context, the role of previously used hypoglycemic agents, including dipeptidyl peptidase 4 (DPP-4) inhibitors, has been modified. DPP-4 inhibitors have a favorable safety profile, do not cause hypoglycemia or weight gain and do not require dose uptitration. Furthermore, they can be administered in patients with chronic kidney disease after dose modification and elderly patients with diabetes. Still, though, they have been undermined to a third line therapeutic choice as they have not been shown to reduce CV events as is the case with SGLT2-i and GLP-1 RA. Overall, DPP-4 inhibitors appear to have a place in the management of patients with diabetes as a safe class of oral glucose lowering agents with great experience in their use. Baishideng Publishing Group Inc 2022-02-15 2022-02-15 /pmc/articles/PMC8855136/ /pubmed/35211246 http://dx.doi.org/10.4239/wjd.v13.i2.85 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Florentin, Matilda Kostapanos, Michael S Papazafiropoulou, Athanasia K Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment |
title | Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment |
title_full | Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment |
title_fullStr | Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment |
title_full_unstemmed | Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment |
title_short | Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment |
title_sort | role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855136/ https://www.ncbi.nlm.nih.gov/pubmed/35211246 http://dx.doi.org/10.4239/wjd.v13.i2.85 |
work_keys_str_mv | AT florentinmatilda roleofdipeptidylpeptidase4inhibitorsintheneweraofantidiabetictreatment AT kostapanosmichaels roleofdipeptidylpeptidase4inhibitorsintheneweraofantidiabetictreatment AT papazafiropoulouathanasiak roleofdipeptidylpeptidase4inhibitorsintheneweraofantidiabetictreatment |